Back

Sejong Medical's 11.3 billion-won Genencell investment falls to zero amid delisting

Verifying
  • Sejong Medical wrote its Genencell investment down to zero and received a delisting decision.
  • 47.5%: Sejong Medical's stock decline over four trading days after the clinical approval announcement.
  • Genencell suspended ES16001 development in May 2023 after recruiting 109 patients.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Sejong Medical's 11.3 billion-won Genencell investment falls to zero amid delisting - CoinPost Terminal